o a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10552951
Filing Date		2005-10-13
First Named Inventor	Willia	ım Ogilvie
Art Unit		3732
Examiner Name	Unkn	own
Attorney Docket Number		81723/5865

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant s Appear	
	1	5645605		1997-07-08	Klawitter			
	2	5782927		1998-07-21	Klawitter et al.			
	3	6425920		2002-07-30	Hamada			
	4	6436146		2002-08-20	Hassier et al.			
	5	6699292		2004-03-02	Ogilvie et al.			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee of Applicant		Releva	Columns,Lines where nt Passages or Relevant s Appear	
	1	20020035400		2002-03-21	Bryan et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10552951
Filing Date		2005-10-13
First Named Inventor Willia		m Ogilvie
Art Unit		3732
Examiner Name Unkn		own
Attorney Docket Numb	or	81723/5865

Date Considered

	2	20030009224	2003-01-09		Kuras				
	3	20050033426	2005-02-10		Ogilvie et al.				
	4	20050119757	200	05-06-02	Hassier et al.				
If you wis	h to a	dd additional U.S. Publi	shed Applica	ation citatio	n information p	please click the Ad	d buttor	n. Add	
			FO	REIGN PA	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind			Applicant of cited		Pages, Columns, Lines where Relevant Passages or Relevan Figures Appear	т.
	1								
If you wis	h to a	dd additional Foreign P	atent Docum	ent citation	information pl	lease click the Add	button	Add	
			NON-PA	TENT LIT	ERATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (blook, magazine, journal, serial, symposium, catalsg, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.							Тs		
1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
FXAMINER SIGNATURE									

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

	Application Number		10552951	
INFORMATION DIGGS COURS	Filing Date		2005-10-13	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Willia		im Ogilvie	
(Not for submission under 37 CFR 1.99)	Art Unit		3732	
(Not lot submission under or of it issay	Examiner Name Unkno		own	
	Attorney Docket Number		81723/5865	

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. * *Projectioned projection pr

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10552951	
Filing Date		2005-10-13	
First Named Inventor	William Ogilvie		
Art Unit		3732	
Examiner Name	Unkn	own	
Attorney Docket Number		81723/5865	

CERTIFICATION STATEMENT

Please see	37 CFR	1 97 ar	nd 1 98 to	make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(4)(2)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/jjs/	Date (YYYY-MM-DD)	2006-06-29
Name/Print	JAMES J. SCHUMANN	Registration Number	20856

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.